EVALUATION OF EFFICACY AND TOXICITY OF NEOADJUVANT CHEMOTHERAPY WITH DOSE-DENSE DOXORUBICIN, CISPLATIN, AND PACLITAXEL IN PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

Triple-negative breast cancer (TNBC) is characterized by an aggressive behavior, highly sensitivity to chemotherapy, early recurrence, and also the absence of known targets for targeted therapies. TNBC is extremely impotant search for intensive regimens of neoadjuvant chemotherapy, because of insufficient effectiveness of conventional therapies. The aim of the study was to evaluate the efficacy and toxicity of cisplatin, doxorubicin, paclitaxel in patients with early breast cancer with triple-negative phenotype in preoperative mode. The study included 41 patients with early breast cancer, triple negative phenotype (T1–2 N0–1M0). Patients were treated with cisplatin 30 mg/m2 / IV., Doxorubicin 25 mg/m2 / IV., Paclitaxel  100 mg/m2 / IV. weekly for planned 8 weeks  with G-CSF 300 mcg 2–4 days followed by surgery. The rate of objective response was 38/40 (95%) complete response – 12/40 (30%), partial regression – 26/40 (65%), stabilization – 2/40 (50%). 40 hftients were treated with surgery, 26/40 (65%) achieved a complete pathological regression. 2-year disease-free survival – 89.4%. 2-year overall survival – 95.1%. Combination of cisplatin, doxorubicin, paclitaxel, it proved its high efficacy in patients with early breast cancer with triple-negative phenotype, despite it’ high toxicity. 

1. Liedtke C., Mazouni C., Hess K. R. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer // J Clin Oncol.– 2008. V. 26.– I. 8.– P. 1275–1281.

2. von Minckwitz G.I., Untch M., Blohmer J. U. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes // J Clin Oncol.– 2012.– V. 30.– I. 15.– P. 1796–1804.

3. Esserman L. J., Berry D. A., DeMichele A. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY1 TRIAL – CALGB150007/150012, ACRIN6657 // J Clin Oncol.– 2012.– V. 30.– I. 26.– P. 3242–3249.

4. Darb-Esfahani S.I., Loibl S., M ller B. M. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy // Breast Cancer Res.– 2009.– V. 11.– I. 5.– R69.

5. Rouzier R., Perou C. M., Symmans W. F. Breast cancer molecular subtypes respond differently to preoperative chemotherapy // Clin Cancer Res.– 2005.– V. 11.– I. 16.– P. 5678–5685.

6. Carey L. A., Dees E. C., Sawyer L. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes // Clin Cancer Res.– 2007.– V. 13.–– I. 8.– P. 2329–2334.

7. Wang S., Yang H., Tong F. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer // Gan To Kagaku Ryoho.– 2009.– V. 36.– I. 2.– P. 255–258.

8. Ring A. E., Smith I. E., Ashley S. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer // Br J Cancer.– 2004.– V. 91.– I. 12.– P. 2012–2017.

9. Guarneri V., Broglio K., Kau S. W. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors // J Clin Oncol.– 2006.– V. 24.– I. 7.– P. 1037–1044.

10. Rojas K. I. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer (TNBC) in a Peruvian institute // ASCO Meeting Abstracts.– 2013.– V. 31.– S. 15.– E12038.

11. Torrisi R., Balduzzi A., Ghisini R. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel // Cancer Chemother Pharmacol.– 2008.– V. 62.– I. 4.– P. 667–672.

12. Silver D. P., Richardson A. L., Eklund A. C. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer // J Clin Oncol.– 2010.– V. 28.– I. 7.– P. 1145–1153.

13. Byrski T., Huzarski T., Dent R. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients // Breast Cancer Res Treat.– 2014.– V. 147.– I. 2.–P. 401–405.

14. Frasci G., Comella P., Rinaldo M. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triplenegative large operable breast cancer // Ann Oncol.– 2009.– V. 20.– I. 7.– P. 1185–1192.

15. Yerushalmi R., Hayes M. M., Gelmon K. A. A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers // Clin Breast Cancer.– 2009.– V. 9.– I. 3.– P. 166–172.

16. Allred D. C., Harvey J. M., Berardo M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis // Mod Pathol.– 1998.– V. 11.– I. 2.– P. 155–168.

17. Bloom H. J., Richardson W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years // Br J Cancer.– 1957.– V. 11.– I.– 3.– P. 359–377.

18. Chevallier B., Roche H., Olivier J. P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate // Am J Clin Oncol.– 1993.– V. 16.– I. 3.– P. 223–228.

19. Wang J., Shi M., Ling R. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial // Radiother Oncol.– 2011.– V. 100.– I. 2.– P. 200–204.